Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparative Effectiveness Needs Holistic Value Measures – Amgen Exec

Executive Summary

As momentum for payers to put more emphasis on pharmaceuticals' comparative effectiveness data, those involved in implementing CE programs need to recognize the "multi-dimensional" aspect of a drug's value, Amgen VP of Global Coverage & Reimbursement and Global Health Economics Josh Ofman said
Advertisement

Related Content

BIO Taps Big Pharma Execs for Federal Comparative Effectiveness Research Board Nominations
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions
Advertisement
UsernamePublicRestriction

Register

PS050437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel